Publications by authors named "K Yokoo"
Introduction: Compared to platinum-based therapies, a combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) has demonstrated improved outcomes in advanced non-small cell lung cancer (NSCLC), albeit with higher rates of immune-related adverse events (irAEs). This multicenter retrospective study evaluated the efficacy and safety of nivolumab and ipilimumab with or without chemotherapy (NI and NICT) in real-world clinical settings.
Methods: We enrolled 215 treatment-naïve NSCLC patients who received NI or NICT between December 2020 and May 2023 at 14 institutions in Japan.
Background: In the first-line treatment of elderly patients with advanced-stage non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%), this study aimed to determine whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected.
Methods: We performed a retrospective multicenter study (sub-analysis of the HOT/NJLCG2001 trial) of 299 patients with NSCLC with high PD-L1 expression who received MONO or COMB as the first-line treatment between December 2018 and January 2020. We selected patients aged 75 years and older and assessed the clinical efficacy and toxicity.
A 71-year-old man with silicosis was treated for infection. Antimycobacterial treatment for was terminated 1 year after a negative test result for the bacteria on sputum examination. One year following the treatment, the patient developed pneumonitis.
View Article and Find Full Text PDFBackground: Non-small-cell lung cancer (NSCLC) is associated with a high incidence of brain metastasis (BM), and the prognosis of patients with NSCLC and BM is poor. This study aimed to identify the prognostic factors and elucidate the survival rates of Japanese patients with NSCLC and BM at initial diagnosis.
Methods: HOT 1701 is a retrospective multicenter study of patients with NSCLC and BM at initial diagnosis.
Article Synopsis
- The study assesses the long-term outcomes of patients with nonsmall cell lung cancer (NSCLC) and high PD-L1 expression treated with either pembrolizumab alone (MONO) or in combination with chemotherapy (COMB).
- A total of 298 patients were observed, with COMB showing better overall survival (33.7 months) compared to MONO (17.2 months), although after adjusting for various factors, the advantage of COMB over MONO was not statistically significant.
- The findings suggest that while COMB may be beneficial in certain patients, both treatment options have similar discontinuation rates, indicating comparable tolerability.